Sionna Therapeutics, Inc. (SION) stock
Close on Nov 11, 2026Market cap $167.29MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $167.29M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.70
- Dividend yield
- –
- Free cash flow yield
- -47.59%
Fundamentals
- Net income
- -$109.52M
- EPS, diluted
- -$2.44
- Free cash flow
- -$79.61M
- Book value per share
- $5.32
- Diluted shares
- 45M
Trading
- Next earnings
- Mar 1, 2027 (estimated, before the open)
- Previous close
- $3.70
- Open
- $3.74
- Day's range
- $3.68 – $3.85
- Volume
- 647,134
- Average volume (20 days)
- 963,196
- Index membership
- Russell 2000 (since Jun 2025), Russell 3000 (since Aug 2025)
- 52-week range
- $3.19 – $54.97
- RSI (14 days)
- 36.6
- Volatility (1 year)
- 121.9%
- Relative volume
- 0.35×
On 2 of our idea lists: Net-nets, More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | SION | S&P 500 | Difference | SION per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -24.5% | -2.4% | −22.1 pts | ||
| 3 months | -27.5% | -1.2% | −26.3 pts | ||
| Year to date | -91.0% | +12.3% | −103.3 pts | ||
| 1 year | -89.9% | +12.4% | −102.3 pts |
Three years at a glance
Fiscal years 2023 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Sionna Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- News
- Results
- Results
- Results
About Sionna Therapeutics
Pharmaceutical Preparations
This clinical-stage biopharmaceutical company discovers and develops small-molecule therapeutics to treat cystic fibrosis by restoring CFTR protein function. Its pipeline centers on nucleotide binding domain 1 (NBD1) stabilizers, notably lead candidates SION-719 and SION-451, designed to correct defects caused by the F508del genetic mutation. The company also advances complementary CFTR modulators, including transmembrane domain 1 correctors such as SION-2222 and SION-2851, the intracellular loop 4 corrector SION-109, and the potentiator SION-3067. Its product candidates are designed either to be administered alongside the existing standard of care or paired into proprietary dual-combination therapies. The company targets people living with cystic fibrosis, particularly individuals carrying the F508del mutation.
Company profile, executives and historySionna Therapeutics stock: common questions
What is Sionna Therapeutics's stock price?
SION closed at $3.70 on Nov 11, 2026, up 0.00% on the day. Over the past 52 weeks it traded between $3.19 and $54.97.
What is Sionna Therapeutics's market cap?
Sionna Therapeutics was worth $167.29M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is SION's P/E ratio?
Sionna Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$2.44), so it has no meaningful P/E ratio.
Does Sionna Therapeutics pay a dividend?
No. Sionna Therapeutics has not paid a cash dividend over the last twelve months.
When does Sionna Therapeutics report earnings next?
Sionna Therapeutics is expected to report Q4 FY2026 results on Mar 1, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has SION stock performed over the past year?
Including dividends, SION returned -89.9% over the past year, against +12.4% for the S&P 500.
How many SION shares are sold short?
4M shares were sold short at the latest FINRA report, 18.67% of the float, or 4.1 days of average trading volume.
Who are Sionna Therapeutics's competitors?
Companies most similar to Sionna Therapeutics by business, industry and size include DSGN, TVRD, LRMR, KROS, TRDA.
See a number that looks wrong?